Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19

Yahya Shaikh; Ishaan Gupta; Sophia Purekal; MaryJane E. Vaeth; Maisha Foyez; Charles D. Callahan; Maryam Elhabashy; James R Ficke; Albert W. Wu; Paul Auwaerter; Melinda E. Kantsiper; Zishan K. Siddiqui

Este articulo es un Preprint

Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.

Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.

Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19

Yahya Shaikh; Ishaan Gupta; Sophia Purekal; MaryJane E. Vaeth; Maisha Foyez; Charles D. Callahan; Maryam Elhabashy; James R Ficke; Albert W. Wu; Paul Auwaerter; Melinda E. Kantsiper; Zishan K. Siddiqui.

Afiliación

Yahya Shaikh; MITRE Corporation, Baltimore, Maryland, USA
Ishaan Gupta; Johns Hopkins University School of Medicine
Sophia Purekal; Baltimore Convention Center Field Hospital, Baltimore, Maryland, USA
MaryJane E. Vaeth; Baltimore Convention Center Field Hospital, Baltimore, Maryland, USA
Maisha Foyez; Baltimore Convention Center Field Hospital, Baltimore, Maryland, USA
Charles D. Callahan; Department of Population Health, University of Maryland Medical Center, Baltimore, Maryland, USA
Maryam Elhabashy; University of Maryland, Baltimore County, Maryland, USA
James R Ficke; Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA
Albert W. Wu; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Paul Auwaerter; The Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Melinda E. Kantsiper; Division of Hospital Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Zishan K. Siddiqui; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22277360

ABSTRACT

ABSTRACT

Background and MethodsWe conducted a single center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021 and May 14, 2021. ResultsAmong the 2,406 eligible participants, African Americans were significantly more likely to underutilize mAb treatment (OR 1.8; 95% CI 1.5-2.1) and miss treatment opportunities due to monoclonal hesitancy (OR 1.7, 95% CI 1.3-2.1). ConclusionAddressing racial disparities in mAb delivery is an opportunity to bridge the racial inequities in COVID-19 care.

Licencia

cc_by_nc

Texto completo

Añadir a Mi BVS

Imprimir

XML

Buscar en Google

Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Rct Idioma: En Año: 2022 Tipo del documento: Preprint

Texto completo

Añadir a Mi BVS

Imprimir

XML

Buscar en Google

Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Rct Idioma: En Año: 2022 Tipo del documento: Preprint